Treatment of Pruritus With Maralixibat in Early-Stage Chronic Graft Dysfunction of a Child With Alagille Syndrome
This article focuses on the treatment of pruritus using Maralixibat. The case study involves a child diagnosed with Alagille Syndrome who is experiencing early-stage chronic graft dysfunction. The content provided appears to be a journal's navigation and registration interface rather than the full article.
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to "Moderate Buy" at Royal Bank Of Canada
Royal Bank Of Canada upgraded Mirum Pharmaceuticals (NASDAQ:MIRM) to a "moderate buy" rating. Other firms like Evercore, Leerink Partners, HC Wainwright, Citigroup, and Wall Street Zen have also issued positive ratings, with a consensus price target of $110.17. The article also details recent insider stock sales by SVP Jolanda Howe and CFO Eric Bjerkholt, and mentions institutional investor activity.
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects
Mirum Pharmaceuticals (MIRM) has experienced significant share price momentum, driven by its focus on rare and orphan liver diseases and an expanding commercial portfolio. While the stock is currently seen as undervalued with a fair value estimate of $106.60 against a recent price of $105.10, the company faces execution risks related to its key therapy, Livmarli, and upcoming late-stage PSC data. Investors are encouraged to review the company's financial details and risk factors to form an independent view.
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD By Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) stock reached an all-time high of $106.27, surpassing its 52-week high, following an impressive 101.38% increase over the past year. The company's strong performance is attributed to investor confidence, positive product pipeline developments, revenue growth, and significant acquisitions like Bluejay Therapeutics. Analysts remain bullish, with high price targets, reflecting optimism about Mirum's future prospects in the rare liver disease market.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will report its fourth quarter and year-end 2025 financial results on February 25, 2026. The company will also host a conference call at 4:30 PM ET / 1:30 PM PT to discuss these results and recent corporate progress. Mirum is a rare disease company with a global footprint, focusing on approved products such as LIVMARLI® and CHOLBAM®, and has a clinical-stage pipeline including volixibat and MRM-335H.
RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation
RBC Capital has initiated coverage of Mirum Pharmaceuticals (MIRM) with an Outperform recommendation. Analysts project a 13.77% upside from its current price, with an average one-year price target of $116.99/share. Institutional ownership shows a slight decrease in the number of funds, but a 2.09% increase in total shares owned, indicating a bullish outlook with a put/call ratio of 0.21.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Mirum Pharmaceuticals, Inc. announced that it will report its fourth quarter and full-year 2025 financial results on February 25, 2026. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results and recent corporate progress. Mirum Pharmaceuticals specializes in rare diseases, with approved products like LIVMARLI®, CHOLBAM®, and CTEXLI®, and a pipeline including volixibat and brelovitug.
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD
Mirum Pharmaceuticals Inc. (MIRM) stock has hit an all-time high of $106.27 USD, surpassing its 52-week high, driven by strong investor confidence and pipeline developments. The company reported preliminary unaudited net product sales of $520 million for 2025 and projected $630-650 million for 2026, alongside acquiring Bluejay Therapeutics. Analysts maintain a bullish outlook, with several firms raising price targets due to consistent performance and product potential.
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Mirum Pharmaceuticals (MIRM) is expected to report a significant year-over-year increase in earnings and revenue for Q4 2025. The company's Most Accurate Estimate for EPS is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +675.00% and a Zacks Rank of #3, suggesting a strong likelihood of beating EPS estimates. Investors are advised to consider other factors beyond earnings beats or misses, though the combination of a positive Earnings ESP and Zacks Rank increases the odds of success.
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM
TimesSquare Capital Management LLC has made a new $22.04 million investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), acquiring 300,649 shares in the third quarter. Insider activity shows Director Patrick J. Heron increased his stake significantly, while other insiders sold shares. Analysts maintain a "Moderate Buy" rating with a consensus target price of $107.25, reflecting positive sentiment towards the biopharmaceutical company.
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) is highlighted as a strong candidate for the Minervini Growth Momentum strategy, which combines strict technical rules with robust fundamental growth. The article details how MIRM meets Minervini's Trend Template for technical strength and exhibits significant, accelerating growth in EPS and sales, supported by positive analyst revisions. This combination suggests the stock is well-positioned for potential major gains.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals announced inducement awards granted to 37 new employees, comprising stock options, restricted stock units (RSUs), and performance stock units (PSUs). These awards, approved by the Compensation Committee, are designed to align with Nasdaq Listing Rule 5635(c)(4) and vest over several years based on continued service and, for PSUs, on achieving specific net product sales targets in 2027 and 2028. This move aims to incentivize and retain key talent within the company.
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Health Canada’s LIVMARLI Approval And Recent Share Price Momentum
Mirum Pharmaceuticals (MIRM) shares are under scrutiny following Health Canada's approval of LIVMARLI for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis. The regulatory win has contributed to significant recent share price momentum, with the stock up 16.56% over 30 days and 42.57% over 90 days. Despite this surge, a widely followed fair value narrative still suggests the stock is approximately 5.3% undervalued, prompting questions about continued buying opportunities amidst anticipated future growth driven by late-stage pipeline catalysts.
Mirum Pharmaceuticals Grants Stock Awards to New Employees
Mirum Pharmaceuticals has granted significant stock awards to 37 new employees, including 163,040 non-qualified stock options, 219,090 restricted stock units (RSUs), and 48,880 performance stock units (PSUs). These awards, compliant with Nasdaq Listing Rule 5635(c)(4), are designed to attract and retain talent, ensure long-term commitment, and align employee incentives with the company's performance and strategic goals in the rare disease sector.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. announced inducement grants to 37 new employees, including non-qualified stock options, restricted stock units (RSUs), and performance stock units (PSUs). These awards, approved by the Compensation Committee, are designed to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The grants have specific vesting schedules tied to continued service and, for PSUs, to the achievement of net product sales targets in 2027 and 2028.
New Mirum staff get stock grants, some tied to 2027–28 net sales
Mirum Pharmaceuticals (Nasdaq: MIRM) has granted inducement awards, including non-qualified stock options, restricted stock units (RSUs), and performance stock units (PSUs), to 37 new employees. These awards are aimed at aligning employee interests with company growth, with PSUs specifically tied to achieving certain net product sales levels in 2027 and 2028. The grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) is presented as a high-growth momentum stock with a strong technical breakout setup. The company demonstrates accelerated earnings and sales growth, positive analyst revisions, and robust cash flow. Technically, MIRM shows a solid uptrend, outperforming the market and its industry, with its price above all major moving averages, suggesting a potential continuation of its upward trajectory after a period of consolidation.
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Candriam S.C.A. has increased its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 8.0%, acquiring an additional 30,021 shares, bringing its total holdings to 403,026 shares valued at $29.55 million. Other institutional investors like Eventide, Geode, BNY Mellon, and JPMorgan also boosted their positions. Despite notable insider selling totaling $4.35 million over the past 90 days, Mirum Pharmaceuticals maintains a "Moderate Buy" consensus rating from analysts with an average target price of $107.25.
How Investors Are Reacting To Mirum Pharmaceuticals (MIRM) Securing Health Canada PFIC Nod For LIVMARLI
Mirum Pharmaceuticals received Health Canada authorization for LIVMARLI to treat cholestatic pruritus in PFIC patients aged 12 months and older, a significant expansion supported by robust Phase 3 trial data. While this authorization strengthens Mirum's investment narrative by reinforcing its clinical profile and global footprint, the company still faces high expectations due to its strong stock performance, premium sales multiples, and ongoing losses. Investors are now focused on Mirum's ability to achieve its 2026 product revenue guidance and transition to consistent profitability, with various fair value estimates for the stock highlighting differing perspectives on its future.
Mirum Pharmaceuticals expands portfolio in rare disease drug focus
Mirum Pharmaceuticals is actively expanding its focus on developing drugs for rare diseases. CEO Chris Peetz highlighted the company's commitment to these specialized treatments, emphasizing evolving approaches in drug development and commercialization. Mirum aims to lead in the biopharmaceutical landscape by addressing unmet medical needs and improving patient outcomes in the rare disease sector.
Mirum Buyout Of Bluejay Shifts Rare Liver Story Beyond Livmarli
Mirum Pharmaceuticals has announced the acquisition of Bluejay Therapeutics, adding a late-stage hepatitis D candidate to its rare liver disease pipeline. This strategic move aims to diversify Mirum's portfolio beyond its existing bile acid products, reducing reliance on a single therapy and broadening treatment options. The acquisition positions Mirum to build a more comprehensive rare liver disease platform, moving away from a single-product focus, while balancing the opportunities of diversification against increased operational complexity and market risks.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for treating cholestatic pruritus in Alagille syndrome (ALGS) patients weighing 22 kg or more. This new tablet option complements the existing oral solution, providing greater dosing flexibility for patients as they age. The authorization aims to improve treatment adherence and continuity of care for ALGS patients experiencing chronic itching.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals has announced that Health Canada has authorized its LIVMARLI® tablet formulation for treating cholestatic pruritus in patients with Alagille syndrome (ALGS). This new tablet option complements the existing oral solution, providing greater dosing flexibility, particularly for older patients weighing over 22 kg. The authorization aims to support continuity of care and improve treatment adherence for individuals with this rare genetic disorder.
Mirum Pharmaceuticals Stumbles on Health Canada Approval
Mirum Pharmaceuticals (NASDAQ: MIRM) saw its shares dip after announcing Health Canada's authorization of LIVMARLI® (maralixibat) for treating cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). This approval offers a new treatment option for PFIC patients aged 12 months and older, with both oral solution and tablet formulations available. Despite the positive regulatory news, the company's stock experienced a 2.2% drop.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals has received Health Canada authorization for a tablet formulation of LIVMARLI (maralixibat) to treat cholestatic pruritus in Alagille syndrome (ALGS) patients. This new tablet option is designed for patients weighing 22 kg or more who can swallow tablets, complementing the existing oral solution for younger patients. This authorization provides greater dosing flexibility and aims to support treatment adherence and continuity of care for ALGS patients as they age.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals has received Health Canada authorization for its drug LIVMARLI® (maralixibat) for treating cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). This authorization includes both oral solution and tablet formulations to allow for flexible dosing. The decision is supported by data from the Phase 3 MARCH study, which showed a statistically significant reduction in pruritus severity with LIVMARLI treatment.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and tablet formulation for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). This authorization covers both oral solution and tablet formulations, providing flexible dosing options for patients. The decision is supported by data from the Phase 3 MARCH study and is expected to significantly improve the quality of life for PFIC patients suffering from severe pruritus.
Mirum Pharmaceuticals (MIRM) Price Target Increased by 10.50% to 116.99
The average one-year price target for Mirum Pharmaceuticals (MIRM) has been increased by 10.50% to $116.99 per share, up from $105.88. This new target represents a 10.95% increase from the last closing price of $105.45. Institutional ownership data shows 464 funds holding positions, with total shares owned increasing by 2.30% in the last three months, and a bullish put/call ratio of 0.21.
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Bluejay Deal And Strong 2025 And 2026 Revenue Update
Mirum Pharmaceuticals (MIRM) recently completed its acquisition of Bluejay Therapeutics and exceeded its 2025 net product sales guidance, while also providing a strong 2026 revenue outlook. Investors have responded positively to these developments, indicated by significant short-term and long-term share price increases. The article explores whether Mirum is still undervalued despite its recent growth and premium sales multiple, highlighting both the potential Upside from pipeline catalysts and the risks associated with underperforming expectations.
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe recently sold 968 shares of the company's stock for $99,994.40, reducing her stake by 17.69%. This follows earlier sales in January. Despite these insider sales, Mirum Pharmaceuticals' stock traded up 1.6% to $105.45, near its 52-week high, and analysts maintain a "Moderate Buy" rating with an average target price of $107.25.
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $940,856.40 in Stock
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz sold 9,108 shares of the company's stock for $940,856.40 on February 2nd, reducing his stake by 5.38%. This transaction follows previous sales in January. The company reported strong quarterly revenue and beat EPS estimates but remains unprofitable, while analysts have a "Moderate Buy" rating with an average price target of $107.25.
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock
Jolanda Howe, SVP at Mirum Pharmaceuticals, sold 968 shares of Mirm stock worth $99,997 on February 2, 2026, primarily to cover tax obligations from restricted stock units. This insider sale follows encouraging news for Mirum, including strong 2025 sales, optimistic 2026 revenue projections, and the acquisition of Bluejay Therapeutics. Analysts have maintained positive ratings and raised price targets for Mirum based on these developments and the potential of key drug candidates.
Mirum Pharma president & COO sells $271k in stock
Mirum Pharmaceuticals' President and COO, Peter Radovich, sold 2,631 shares of common stock for approximately $271,791 to cover tax withholding obligations. This transaction leaves him with 20,655 directly owned shares. Amidst this insider sale, the company reported strong preliminary unaudited net product sales for 2025, topping prior guidance, and provided an optimistic 2026 revenue forecast. Analyst firms like H.C. Wainwright, Baird, and Citizens have reiterated positive ratings and raised price targets for Mirum, citing promising drug candidates and robust sales.
Y Intercept Hong Kong Ltd Takes Position in Mirum Pharmaceuticals, Inc. $MIRM
Y Intercept Hong Kong Ltd has acquired 11,025 shares of Mirum Pharmaceuticals, Inc. valued at approximately $808,000, as detailed in recent SEC filings. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $107.25, after several recent target increases and upgrades. Mirum Pharmaceuticals, a biopharmaceutical company focused on rare cholestatic liver diseases, reported strong Q3 earnings, beating analyst expectations.
Mirum doubles down on diversified rare disease strategy
Mirum Pharmaceuticals is differentiating itself in the rare disease space by building a diverse portfolio of therapies, rather than focusing on a single product. This strategy, highlighted by acquisitions like Bluejay Therapeutics and Travere Therapeutics' bile acid product portfolio, aims to create a more sustainable business model and have a greater impact on underserved patient populations. It also positions Mirum to be a partner of choice for smaller, single-product rare disease companies struggling with funding or deprioritized assets within larger corporations.
Mirum Pharma CEO Peetz sells $941k in shares
Mirum Pharmaceuticals CEO Christopher Peetz sold 9,108 shares of company stock for a total of $940,888 to cover tax obligations from vested restricted stock units. The biopharmaceutical company is trading near its 52-week high with a 110% return over the past year. Analysts remain highly optimistic about Mirum's prospects, with recent news including strong preliminary 2025 sales, an acquisition of Bluejay Therapeutics, and raised price targets from several analyst firms.
Mirum Pharmaceuticals (MIRM) Is Up 6.5% After Bluejay Acquisition and 2026 Sales Outlook Update - What's Changed
Mirum Pharmaceuticals (MIRM) recently reported a rare net profit in Q3 2025, issued bullish 2026 sales guidance of US$630M-US$650M, and acquired Bluejay Therapeutics for US$620M to expand its rare liver disease portfolio. These strategic moves and the advancing volixibat program deepen Mirum's focus on rare liver disorders, but also raise execution challenges and introduce new clinical, regulatory, and cost risks. The market appears willing to overlook short-term margin drags, signaling a belief in the company's long-term potential for sustainable profitability.
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD By Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) stock recently reached an all-time high of $103.94, driven by strong revenue growth and positive developments like exceeding 2025 sales guidance and acquiring Bluejay Therapeutics. Despite being considered overvalued and not profitable in the last year, the company maintains a "GREAT" Financial Health Score and has received increased price targets from analysts due to its robust pipeline and market performance.
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD
Mirum Pharmaceuticals stock has reached an all-time high of $103.94, driven by a 112.43% increase over the past year and substantial revenue growth of 53.66%. The company has also reported strong preliminary net product sales for 2025 and provided an optimistic revenue outlook for 2026, further bolstered by its acquisition of Bluejay Therapeutics and positive analyst ratings. Despite its "GREAT" financial health score, the stock is considered overbought and potentially overvalued compared to its fair value.
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Atle Fund Management AB
Atle Fund Management AB reduced its stake in Mirum Pharmaceuticals (NASDAQ: MIRM) by 12.4% in the third quarter, selling 13,307 shares but still holding 93,605 shares valued at $6.86 million, making it their 16th largest holding. Conversely, Director Patrick J. Heron significantly increased his ownership by purchasing 131,425 shares for nearly $9 million. Analysts largely maintain a "Moderate Buy" rating for Mirum with a consensus price target of $107.25, following a quarter where the company exceeded EPS and revenue estimates, despite remaining unprofitable.
Is Mirum Pharmaceuticals on a Strong Path to Profitability?
Mirum Pharmaceuticals saw profitability in the third quarter of 2025, suggesting progress towards consistent green on its bottom line. However, revenue growth is projected to slow in 2026, and a recent $620 million acquisition of Bluejay Therapeutics is expected to negatively impact short-term profitability due to associated costs, despite potential long-term benefits. While the stock has strong momentum, investors should be aware of increased risk and limited upside given declining sales growth and the acquisition's impact.
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?
H.C. Wainwright has raised its price target on Mirum Pharmaceuticals (NASDAQ: MIRM) twice in two weeks, now set at $130, due to bullish guidance for 2026. Analyst Swayampakula Ramakanth anticipates 2026 will be a pivotal year for volixibat's clinical evaluation, with a potential launch in early 2027. Despite the current analyst consensus median price target of $103, Ramakanth's new target suggests an almost 31% upside, signaling strong confidence in Mirum's future performance.
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?
H.C. Wainwright has raised its price target on Mirum Pharmaceuticals (MIRM) for the second time in two weeks, from $102 to $130, maintaining a Buy rating. This revised target is based on the company's bullish 2026 guidance, particularly for its drug volixibat, which is expected to enter clinical evaluation for two chronic immune-mediated cholestatic liver diseases. The analyst anticipates volixibat could launch as early as the first half of 2027 and believes 2026 will be a pivotal year for its progress.
11 Best Stocks to Buy for Investment
This article identifies Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) as one of the best stocks to buy for investment, citing analyst upgrades and strong performance. The company's stock has surged over 91% in the last six months due to bullish guidance for 2026 and potential advancements in its drug volixibat. Analysts have a median price target of $103, with some individual targets reaching $130, implying significant upside.
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Mirum Pharmaceuticals (NASDAQ:MIRM) shares have surged 25% in the last month, contributing to a 105% gain over the past year. Despite this strong performance, the company's
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Mirum Pharmaceuticals (NASDAQ:MIRM) shares have increased 25% in the last month and 105% over the last year, despite its price-to-sales (P/S) ratio of 12.6x being similar to the industry median. The company's revenue growth of 54% last year is expected to slow to 22% annually over the next three years, significantly less than the industry's predicted 133% growth. Analysts suggest the current P/S ratio may not be justified given the weaker revenue outlook, potentially risking future share price declines if sentiment shifts.
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Mirum Pharmaceuticals (NASDAQ: MIRM) shares have surged 25% in the last month and 105% over the past year, despite its price-to-sales ratio being similar to the biotech industry average. The company has shown impressive past revenue growth of 54% last year, but analysts forecast weaker future growth of 22% compared to the industry's predicted 133%. This discrepancy suggests that investors might be overlooking potential risks associated with its subdued growth outlook, as the similar P/S ratio may not be sustainable given the lower growth projections.
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com
Director Patrick J. Heron purchased 131,425 shares of Mirum Pharmaceuticals Inc. for $8.99 million and indirectly acquired an additional 159,277 shares through Frazier Life Sciences X, L.P. The company also reported strong preliminary net product sales for 2025, exceeding guidance, and projected significant revenue growth for 2026. Mirum recently acquired Bluejay Therapeutics, adding a late-stage chronic hepatitis delta virus treatment, and has received positive analyst ratings and raised price targets.
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m
Director Patrick J. Heron purchased 131,425 shares of Mirum Pharmaceuticals Inc. for approximately $9 million on January 23, 2026, and also indirectly acquired additional shares through a merger. These transactions occurred amidst positive financial news for Mirum, including exceeding 2025 sales guidance and optimistic analyst ratings following its acquisition of Bluejay Therapeutics. The company projects significant growth for 2026, driven by its expanded portfolio.
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics
Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding worldwide rights to brelovitug, a late-stage treatment for chronic hepatitis delta virus (HDV). The acquisition was funded through a combination of cash, Mirum common stock, and private placement financings totaling approximately $268.5 million. Brelovitug has Breakthrough Therapy designation from the FDA, PRIME designation from the EMA, and is currently in Phase 3 trials with data expected in late 2026.
